Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.
Balash et al.·Clinical neuropharmacologyImpact 1.2
Klarer NutzenGRADESehr niedrig82 Zitate
Stichproben = 47 Pat.
Dauermindestens 3 Monate Behandlung…
EndpunktSubjektiver globaler Eindruck
Verblindungn.a.
DesignKohortenstudie
Cannabinoidvollspektrum
Max. Dosis900.0 mg
Applikationinhalativ
”Kernaussage
Medizinisches Cannabis zeigte Verbesserungen bei verschiedenen Parkinson-Symptomen, insbesondere bei Stürzen (r=0,89), Schmerzlinderung (r=0,73), Depression (r=0,64), Tremor (r=0,64), Muskelsteifheit (r=0,62) und Schlaf (r=0,60), verursachte jedoch bei 10,6% der Patienten erhebliche Nebenwirkungen (Verwirrtheit und Halluzinationen), die zum Abbruch führten.
Zusammenfassung
n=47 nicht-demente Parkinson-Patienten (mittlere Krankheitsdauer 10,8±8,3 Jahre, median H&Y Stadium III), retrospektive telefonische Befragung nach ≥3 Monaten Cannabis-Behandlung (mittlere Dauer 19,1±17,0 Monate). Effektstärke (r) für Verbesserungen: Stürze r=0,89, Schmerzreduktion r=0,73, Depression r=0,64, Tremor r=0,64, Muskelsteifigkeit r=0,62, Schlaf r=0,60. Häufigste Nebenwirkungen: Husten (34,9% bei Rauchern), Verwirrtheit und Halluzinationen (jeweils 17%), 10,6% Therapieabbruch wegen Nebenwirkungen.
P
PopulationNicht-demente Parkinson-Patienten unter medizinischem Cannabis (≥3 Monate), n=47, mittleres Alter 64,2 Jahre, medianes H&Y-Stadium III
Background: The use of medical cannabis (MC) is controversial. Support for its benefits is based on small clinical series.
Objective: The aim of this study was to report the results of a standardized interview study that retrospectively assessed the effects of MC on symptoms of Parkinson disease (PD) and its adverse effects in patients treated for at least 3 months.
Methods: The survey used telephone interviews using a structured questionnaire based on subjective global impressions of change for various parkinsonian symptoms and yes/no questions on adverse effects.
Results: Forty-seven nondemented patients with PD (40 men) participated. Their mean age was 64.2 +/- 10.8 years, mean disease duration was 10.8 +/- 8.3 years, median Hoehn and Yahr (H&Y) was stage III. The duration of MC use was 19.1 +/- 17.0 months, and the mean daily dose was 0.9 +/- 0.5 g. The delivery of MC was mainly by smoking cigarettes (38 cases, 80.9%). Effect size (r) improvement for falls was 0.89, 0.73 for pain relief, 0.64 for depression, 0.64 for tremor, 0.62 for muscle stiffness, and 0.60 for sleep. The most frequently reported adverse effects from MC were cough (34.9%) in those who used MC by smoking and confusion and hallucinations (reported by 17% each) causing 5 patients (10.6%) to stop treatment.
Conclusions: Medical cannabis was found to improve symptoms of PD in the initial stages of treatment and did not cause major adverse effects in this pilot, 2-center, retrospective survey. The extent of use and the reported effects lend support to further development of safer and more effective drugs derived from Cannabis sativa.